Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Upper GI Tract Bleeding: Hematemesis, Hematochezia, or Melena?
From Risk Stratification to Post-Endoscopic Management
- Obesity, Nutrition, and Mental Health
Depression, Binge Eating, Internalized Stigma
- From Hypertension to Heart Failure?
When and how to intervene
- Switzerland's First PTH Replacement Therapy
Palopegteriparatide for Chronic Hypoparathyroidism
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Quitting smoking reduces cardiovascular risks
Offer professional support
- CKD and High Blood Pressure
Keeping an Eye on Bidirectional Interactions
- Atherosclerotic Coronary Plaques in High-Risk Patients